ARS-1620 is a quinazoline derivative that functions as a potent, selective, and orally bioavailable covalent inhibitor of the KRAS G12C mutant protein. It is used in research as a targeted compound for studying KRAS G12C-driven cancers.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
(S)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
pharmaceutical raw material
(S)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
pharmaceutical raw material
Exatecan mesylate
pharmaceutical raw material
Imidafenacin
pharmaceutical raw material
Vipivotide tetraxetan
pharmaceutical raw material
Secretin acetate
pharmaceutical raw material
1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one
ZRPZPNYZFSJUPA-UHFFFAOYSA-N
C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=C(C=CC=C4F)O)F
Sourcing this compound?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.